Avanir Pharms., Inc. v. Actavis South Atlantic LLC (D. Del.)

by Robins Kaplan LLP
Contact

Case Name: Avanir Pharms., Inc. v. Actavis South Atlantic LLC, Case No. 1:11-cv-0704-LPS, 2014 U.S. Dist. LEXIS 67111 (D. Del. May 5, 2014) (Stark, J.)

Drug Product and Patent(s)-in-Suit: Nuedexta® (dextromethorphan/quinidine); U.S. Pats. Nos. RE38,115 (“the ’115 patent”), 7,659,282 (“the ’282 patent”), and 8,227,484 (“the ’484 patent”) 

Nature of the Case and Issue(s) Presented: The ’115 patent relates to formulations containing dextromethorphan and quinidine for the treatment of chronic or intractable pain. The ’282 and ’484 patents relate to the use of dextromethorphan and quinidine for the treatment of a neurological disorder known as pseudobulbar affect (“PBA”). Defendants stipulated that their proposed products infringe claims 1-9 of the ’282 patent and claims 1-9, 12, 13, 15, and 17 of the ’484 patent. After a six-day bench trial, the court found that: (i) plaintiffs have not proven by a preponderance of the evidence that defendants infringe claims 18-21 of the ’115 patent, (ii) defendants have failed to prove by clear and convincing evidence that claims 1-9 of the ’282 patent are invalid; (iii) defendants have failed to prove by clear and convincing evidence that claims 1-9, 12, 13, 15, and 17 of the ’484 patent are invalid; and (iv) defendants have failed to prove by clear and convincing evidence that claims 18-21 of the ’115 patent are invalid.

Why Avanir Prevailed: Concerning whether defendants’ ANDA products infringed the ’115 patent, the dispute focused on whether Nuedexta contains a combined unit dosage of dextromethorphan and quinidine that is “therapeutically effective in substantially reducing chronic or intractable pain, without unacceptable side effects.” Nuedexta has been approved by the FDA only to treat PBA. Its package insert provides no statement on treating pain, and none of the Nuedexta clinical studies establish that Nuedexta is “therapeutically effective” in substantially reducing chronic pain. Avanir’s reliance on patient interviews, which are undocumented and lack objective measures of efficacy, provided little evidence in support of its infringement theory.  Moreover, studies measuring the response to Nuedexta among normal subjects experiencing pain are only minimally relevant to whether Nuedexta can effectively treat patients with chronic or intractable pain without causing unacceptable side effects. Therefore, defendants’ ANDA products do not infringe the asserted claims of the ’115 patent.

Concerning whether the prior art renders the ’484 and ’282 patents obvious, defendants argued that the only difference between the prior art and the asserted claims is the dose ranges of quinidine. This, however, ignores the subject matter of the claims as a whole, including the amounts of dextromethorphan and the claimed weight to weight ratios of dextromethorphan and quinidine. Defendants also argued that a person or ordinary skill would have been motivated to modify the dose of quinidine because of safety concerns and industry practice. The court disagreed. Defendants’ evidence for cardiotoxicity pertained only to the far higher antiarrhythmic dose levels of quinidine and the other side effects were associated with dextromethorphan rather than quinidine. In any event, any remaining safety concerns about quinidine taught a person of ordinary skill either to obtain only the lowest efficacious dose or to discontinue use of quinidine altogether. The court found that there would also be no reasonable expectation of success when lowering the dose of quinidine because as a general matter, central nervous system drug development is “challenging and unpredictable, especially in relation to treatment PBA, a disease for which the mechanism for treatment remains unknown.” Next, the court addressed secondary considerations of non-obviousness. The court concluded that a nexus existed between Nuedexta’s commercial success and the claimed invention.  It also found that Avanir presented evidence of unexpected safety benefits and unexpected efficacy in the treatment of PBA.

Finally, since defendants failed to proffer any evidence that a person of ordinary skill would have found the claimed invention of the ’115 patent obvious in light of the “therapeutically effective” limitation, the court concluded that defendants had not shown, by clear and convincing evidence, that the asserted claims of the ’115 patent are obvious.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP
Contact
more
less

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.